SCHEMBL6951280

SCHEMBL6951280

O=C(O)CC(Cc1ccccc1)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 3/20 0.54
SLC1A3 P43003 1/20 0.53
SLC1A2 P43004 1/20 0.53
SLC1A1 P43005 1/20 0.53
ALDH1A1 P00352 1/20 0.51
PIN1 Q13526 3/20 0.49
CYP19A1 P11511 1/20 0.49
POLB P06746 1/20 0.48
NPY5R Q15761 1/20 0.48
PRKCG P05129 1/20 0.47
PRKCB P05771 1/20 0.47
PRKCA P17252 1/20 0.47
PRKCH P24723 1/20 0.47
PRKCE Q02156 1/20 0.47
PRKCD Q05655 1/20 0.47
CA2 P00918 1/20 0.47
CA7 P43166 1/20 0.47
MMP2 P08253 4/20 0.47
MMP9 P14780 3/20 0.47
KAT6A Q92794 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31086814 0.82 MMP2 (0.71) F2SLC1A3SLC1A2SLC1A1ALDH1A1
SCHEMBL3310154 0.82 MMP2 (0.71) F2SLC1A3SLC1A2SLC1A1ALDH1A1
SCHEMBL5189194 0.82 MMP2 (0.71) F2SLC1A3SLC1A2SLC1A1ALDH1A1
SCHEMBL7290941 0.82 MMP2 (0.71) F2SLC1A3SLC1A2SLC1A1ALDH1A1
SCHEMBL8388668 0.80 SLC1A3 (0.60) F2SLC1A3SLC1A2SLC1A1ALDH1A1
SCHEMBL8388664 0.80 SLC1A3 (0.60) F2SLC1A3SLC1A2SLC1A1ALDH1A1
SCHEMBL10830549 0.80 F2 (0.58) F2SLC1A3SLC1A2SLC1A1ALDH1A1
SCHEMBL5780617 0.80 F2 (0.61) F2SLC1A3SLC1A2SLC1A1POLB
SCHEMBL10830546 0.80 F2 (0.58) F2SLC1A3SLC1A2SLC1A1ALDH1A1
SCHEMBL644240 0.79 EEF2K (0.66) SLC1A3SLC1A2SLC1A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610882-B2 Affinity for bradykinin receptors; antithrombotics SANOFI-SYNTHELABO (FR) 2003-08-26 US disclosed
US-20030073641-A1 Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2003-04-17 US disclosed
US-20020115685-A1 Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them SANOFI-AVENTIS (FR) 2002-08-22 US disclosed
US-6433185-B1 ANTIINFLAMMATORY AGENTS; ANALGESICS SANOFI-SYNTHELABO (FR) 2002-08-13 US disclosed
US-6313120-B1 TREATMENT OR PREVENTION OF DISEASES INVOLVING BRADYKININ RECEPTORS SANOFI-SYNTHELABO (FR) 2001-11-06 US disclosed
US-6100278-A COMPOUNDS HAVING AFFINITY FOR BRADYKININ RECEPTORS; ANTIINFLAMMATORY AGENTS SANOFI-SYNTHELABO (FR) 2000-08-08 US disclosed
US-6015812-A N-(arylsulphonyl)amino acid derivatives having bradykinin receptor affinity SANOFI-SYNTHELABO (FR) 2000-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115685-A1 Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them CYP2C9, ADRM1, ADRA1D F2 1898/4885SLC1A3 533/4885SLC1A2 542/4885
US-20030073641-A1 Novel N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them CYP2C9, ADRM1, ADRA1D F2 1898/4885SLC1A3 533/4885SLC1A2 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.